Concepedia

Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases

Emily S. Lebow, Luke Pike, Andrew D. Seidman, Nelson S. Moss, Kathryn Beal, Yao Yu

JAMA Oncology · 2023 · 63 citations · 4 references

DOIFull text

Open access

Concepts

Abstract

This cohort study investigates whether brain metastases that manifest after stereotactic radiotherapy with concurrent antibody-drug conjugates are associated with an increased risk of symptomatic radiation necrosis.

References

4

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

Rupert Bartsch, Anna S. Berghoff, Julia Furtner et al. · Nature Medicine · 2022 · 392 citations · Full text

, , +17

Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors

Penny K. Sneed, Joe Mendez, J.G.M. Vemer-van den Hoek et al. · Journal of neurosurgery · 2015 · 357 citations · Full text

, , +17

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆

Filippo Montemurro, Suzette Delaloge, Carlos H. Barrios et al. · Annals of Oncology · 2020 · 342 citations · Full text

, , +17

Competing risks regression for clustered data

Bo Zhou, Jason P. Fine, Aurélien Latouche et al. · Biostatistics · 2011 · 153 citations · Full text

, , +13